Key result
Sarcoplasmic MxA expression showed 77% sensitivity and 100% specificity for diagnosing dermatomyositis, outperforming RIG-I staining and perifascicular atrophy.
Why the study?
Does sarcoplasmic MxA expression improve diagnostic sensitivity and specificity for dermatomyositis compared to RIG-I and PFA?
Case-Control (n=101)
Does sarcoplasmic MxA expression improve diagnostic sensitivity and specificity for dermatomyositis compared to RIG-I and PFA?
Sarcoplasmic MxA expression is a highly sensitive and specific pathological hallmark for diagnosing dermatomyositis across various autoantibody subgroups.
Answers are grounded in this paper and cite their sources.
May aid biopsy diagnosis of dermatomyositis; leaves open prospective validation before routine use.
AIMS: To elucidate the diagnostic value of sarcoplasmic expression of myxovirus resistance protein A (MxA) for dermatomyositis (DM) specifically analysing different DM subforms, and to test the superiority of MxA to other markers. METHODS: Immunohistochemistry for MxA and retinoic acid-inducible gene I (RIG-I) was performed on skeletal muscle samples and compared with the item presence of perifascicular atrophy (PFA) in 57 DM patients with anti-Mi-2 (n = 6), -transcription intermediary factor 1 gamma (n = 10), -nuclear matrix protein 2 (n = 13), -melanoma differentiation-associated gene 5 (MDA5) (n = 10) or -small ubiquitin-like modifier activating enzyme (n = 1) autoantibodies and with no detectable autoantibody (n = 17). Among the patients, nine suffered from cancer and 22 were juvenile-onset type. Disease controls included antisynthetase syndrome (ASS)-associated myositis (n = 30), immune-mediated necrotizing myopathy (n = 9) and inclusion body myositis (n = 5). RESULTS: Sarcoplasmic MxA expression featured 77% sensitivity and 100% specificity for overall DM patients, while RIG-I staining and PFA reached respectively 14% and 59% sensitivity and 100% and 86% specificity. In any subset of DM, sarcoplasmic MxA expression showed higher sensitivity than RIG-I and PFA. Some anti-MDA5 antibody-positive DM samples distinctively showed a scattered staining pattern of MxA. No ASS samples had sarcoplasmic MxA expression even though six patients had DM skin rash. CONCLUSIONS: Sarcoplasmic MxA expression is more sensitive than PFA and RIG-I expression for a pathological diagnosis of DM, regardless of the autoantibody-related subgroup. In light of its high sensitivity and specificity, it may be considered a pathological hallmark of DM per se. Also, lack of MxA expression in ASS supports the idea that ASS is a distinct entity from DM.
No takes yet. Share an insight, caveat, or question.
Uruha et al. (2018) conducted a case-control in Dermatomyositis (n=101). Sarcoplasmic MxA expression vs. RIG-I expression and perifascicular atrophy (PFA) was evaluated on Sensitivity for pathological diagnosis of dermatomyositis. Sarcoplasmic MxA expression showed 77% sensitivity and 100% specificity for diagnosing dermatomyositis, outperforming RIG-I staining and perifascicular atrophy.
Synapse has enriched 10 related papers. Consider them for comparative context: